Epcoritamab Combination Therapy Shows Significant Improvement in Progression-Free Survival for Newly Diagnosed DLBCL

AbbVie and Genmab have announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5. The trial evaluated epcoritamab, a T-cell engaging bispecific antibody, in combination with standard of care R-CHOP, compared to R-CHOP alone. The risk of disease progression or death was reduced by 51%.